OAM
STOK icon

Oxford Asset Management’s Stoke Therapeutics STOK Stock Holding History

Oxford Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-116,196
Closed -$2.5M – 2071
2019
Q3 		$2.5M Sell
116,196
-66,475
-36% -$1.85M 0.06% 423
2019
Q2 		$5.33M Buy
+182,671
New +$4.91M 0.11% 214

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oxford Asset Management's STOK Position: Q4 2019 in Review

Oxford Asset Management sold out of Stoke Therapeutics (STOK) in Q4 2019, closing a stake of 116,196 shares — an estimated $2.5M sold.

Oxford Asset Management first reported a position in STOK in Q2 2019 and held it in 2 quarters. The position peaked at $5.33M in Q2 2019. 64 funds tracked by Wall St. Rank hold STOK as of Q4 2019.

  • Oxford Asset Management reported no remaining Stoke Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Oxford Asset Management sold 116,196 Stoke Therapeutics shares in Q4 2019, an estimated $2.5M.
  • Oxford Asset Management first reported a position in Stoke Therapeutics in Q2 2019 and held it in 2 quarters.
  • Oxford Asset Management's Stoke Therapeutics position peaked at $5.33M in Q2 2019.
  • 64 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.